Well Lead(SH:603309) Sou Hu Cai Jing·2026-01-10 18:39Core Viewpoint - Vili Medical (603309) is experiencing a significant decline in expected net profit for 2025, primarily due to the poor performance of its wholly-owned subsidiary, Jiangxi Langhe Medical Equipment Co., Ltd. [1][2] Performance Disclosure Highlights - Vili Medical anticipates a net profit attributable to shareholders of 75 million to 95 million yuan for 2025, representing a year-on-year decrease of 66% to 57% [1][2][4] - The net profit after deducting non-recurring items is expected to be between 65 million and 85 million yuan, reflecting a year-on-year decline of 69% to 60% [1][2][4] - The decline in performance is mainly attributed to the operational downturn of Jiangxi Langhe Medical Equipment Co., Ltd., and the company plans to recognize goodwill impairment of 147 million yuan, subject to final audit and assessment results [1][2] Company Announcements Summary - Vili Medical's wholly-owned subsidiary, Hainan Vili Medical Technology Development Co., Ltd., has had its hydrophilic coated visible nasogastric tube included in the fourth batch of innovative drug and medical device product catalog in Hainan Province, which will enhance brand recognition and market competitiveness, although the short-term impact on financial performance is expected to be minimal [2][4] - The company plans to utilize up to 350 million yuan of idle self-owned funds for cash management, investing in low-risk, liquid, and safe financial products with a maximum investment period of 12 months [2][4] - For the year 2026, Vili Medical expects to engage in related party transactions totaling no more than 75 million yuan, with procurement from Guangzhou Shimei Packaging Industry Co., Ltd. not exceeding 15 million yuan and sales to Unoquip GmbH not exceeding 60 million yuan [3][4]